PGC-1α, mitochondrial dysfunction, and Huntington's disease

Free Radical Biology and Medicine

Volumn 62, Issue , 2013, Pages 37-46

  Johri, Ashu ^a   Chandra, Abhishek ^a   Beal, M Flint ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Energy metabolism; Huntington's disease; Mitochondrial dynamics; Mitochondrial dysfunction; Mitophagy; Neurodegeneration; Oxidative stress; PGC 1 ; PPARs; SIRT1; SIRT3; Therapeutics

Indexed keywords

ADENOSINE TRIPHOSPHATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; SIRTUIN 1;

ANTIOXIDANT ACTIVITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME DEFICIENCY; HUNTINGTON CHOREA; MITOCHONDRIAL RESPIRATION; NERVE DEGENERATION; NEUROPROTECTION; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

EID: 84884904263     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2013.04.016     Document Type: Review

References (126)

1. Group, H. s. D. C. R. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Hun-tington's Disease Collaborative Research Group. Cell 72: 971-983; 1993.
2. DiFiglia, M.; Sapp, E.; Chase, K.; Schwarz, C.; Meloni, A.; Young, C.; Martin, E.; Vonsattel, J. P.; Carraway, R.; Reeves, S. A., et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 14: 1075-1081; 1995.
3. Velier, J.; Kim, M.; Schwarz, C.; Kim, T. W.; Sapp, E.; Chase, K.; Aronin, N.; DiFiglia, M. Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways. Exp. Neurol. 152: 34-40; 1998. (Pubitemid 28366964)
4. Caviston, J. P.; Holzbaur, E. L. Huntingtin as an essential integrator of intracellular vesicular trafficking. Trends Cell. Biol. 19: 147-155; 2009.
5. Godin, J. D.; Colombo, K.; Molina-Calavita, M.; Keryer, G.; Zala, D.; Charrin, B. C.; Dietrich, P.; Volvert, M. L.; Guillemot, F.; Dragatsis, I.; Bellaiche, Y.; Saudou, F.; Nguyen, L.; Humbert, S. Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis. Neuron 67: 392-406; 2010.
6. Colin, E.; Zala, D.; Liot, G.; Rangone, H.; Borrell-Pages, M.; Li, X. J.; Saudou, F.; Humbert, S. Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons. EMBO J. 27: 2124-2134; 2008.
7. Gauthier, L. R.; Charrin, B. C.; Borrell-Pages, M.; Dompierre, J. P.; Rangone, H.; Cordelieres, F. P.; De Mey, J.; MacDonald, M. E.; Lessmann, V.; Humbert, S.; Saudou, F. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118 : 127-138; 2004. (Pubitemid 38902819)
8. Zala, D.; Hinckelmann, M. V.; Yu, H.; Lyra da Cunha, M. M.; Liot, G.; Cordelieres, F. P.; Marco, S.; Saudou, F. Vesicular glycolysis provides onboard energy for fast axonal transport. Cell 152: 479-491; 2013.
9. Vonsattel, J. P.; DiFiglia, M. Huntington disease. J. Neuropathol. Exp. Neurol. 57: 369-384; 1998. (Pubitemid 28237321)
10. Johri, A.; Beal, M. F. Mitochondrial dysfunction in neurodegenerative diseases. J. Pharmacol. Exp. Ther. 342: 619-630; 2012.
11. Browne, S. E.; Beal, M. F. The energetics of Huntington's disease. Neurochem. Res. 29: 531-546; 2004. (Pubitemid 38295004)
12. Mochel, F.; Haller, R. G. Energy deficit in Huntington disease: why it matters. J. Clin. Invest. 121: 493-499; 2011.
13. Seong, I. S.; Ivanova, E.; Lee, J. M.; Choo, Y. S.; Fossale, E.; Anderson, M.; Gusella, J. F.; Laramie, J. M.; Myers, R. H.; Lesort, M.; MacDonald, M. E. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum. Mol. Genet 14: 2871-2880; 2005. (Pubitemid 41418792)
14. Choo, Y. S.; Johnson, G. V.; MacDonald, M.; Detloff, P. J.; Lesort, M. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet 13: 1407-1420; 2004. (Pubitemid 39023049)
15. Panov, A. V.; Gutekunst, C. A.; Leavitt, B. R.; Hayden, M. R.; Burke, J. R.; Strittmatter, W. J.; Greenamyre, J. T. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 5: 731-736; 2002. (Pubitemid 34827590)
16. Orr, A. L.; Li, S.; Wang, C. E.; Li, H.; Wang, J.; Rong, J.; Xu, X.; Mastroberardino, P. G.; Greenamyre, J. T.; Li, X. J. N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J. Neurosci. 28: 2783-2792; 2008. (Pubitemid 351398886)
17. Beal, M. F.; Brouillet, E.; Jenkins, B. G.; Ferrante, R. J.; Kowall, N. W.; Miller, J. M.; Storey, E.; Srivastava, R.; Rosen, B. R.; Hyman, B. T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13: 4181-4192; 1993. (Pubitemid 23299942)
18. Zhang, S. F.; Hennessey, T.; Yang, L.; Starkova, N. N.; Beal, M. F.; Starkov, A. A. Impaired brain creatine kinase activity in Huntington's disease. Neurodege-ner. Dis. 8: 194-201; 2011.
19. Mochel, F.; Durant, B.; Meng, X.; O'Callaghan, J.; Yu, H.; Brouillet, E.; Wheeler, V. C.; Humbert, S.; Schiffmann, R.; Durr, A. Early alterations of brain cellular energy homeostasis in huntington disease models. J. Biol. Chem. 287: 1361-1370; 2012.
20. Kim, J.; Moody, J. P.; Edgerly, C. K.; Bordiuk, O. L.; Cormier, K.; Smith, K.; Beal, M. F.; Ferrante, R. J. Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. Hum. Mol. Genet 19: 3919-3935; 2010.
21. Johri, A.; Calingasan, N. Y.; Hennessey, T. M.; Sharma, A.; Yang, L.; Wille, E.; Chandra, A.; Beal, M. F. Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease. Hum. Mol. Genet 21: 11 2 4 -113 7 ; 2 0 12 .
22. Song, W.; Chen, J.; Petrilli, A.; Liot, G.; Klinglmayr, E.; Zhou, Y.; Poquiz, P.; Tjong, J.; Pouladi, M. A.; Hayden, M. R.; Masliah, E.; Ellisman, M.; Rouiller, I.; Schwarzenbacher, R.; Bossy, B.; Perkins, G.; Bossy-Wetzel, E. Mutant hun-tingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nat. Med 17 : 377-382; 2011.
23. Chaturvedi, R. K.; Adhihetty, P.; Shukla, S.; Hennessy, T.; Calingasan, N.; Yang, L.; Starkov, A.; Kiaei, M.; Cannella, M.; Sassone, J.; Ciammola, A.; Squitieri, F.; Beal, M. F. Impaired PGC-1alpha function in muscle in Huntington's disease. Hum. Mol. Genet 18: 3048-3065; 2009.
24. Shirendeb, U.; Reddy, A. P.; Manczak, M.; Calkins, M. J.; Mao, P.; Tagle, D. A.; Reddy, P. H. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Hum. Mol. Genet 20: 1438-1455; 2011.
25. Costa, V.; Giacomello, M.; Hudec, R.; Lopreiato, R.; Ermak, G.; Lim, D.; Malorni, W.; Davies, K. J.; Carafoli, E.; Scorrano, L. Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli. EMBO Mol. Med 2: 490-503; 2010.
26. Bossy-Wetzel, E.; Petrilli, A.; Knott, A. B. Mutant huntingtin and mitochon-drial dysfunction. Trends Neurosci. 31: 609-616; 2008.
27. Reddy, P. H.; Mao, P.; Manczak, M. Mitochondrial structural and functional dynamics in Huntington's disease. Brain Res. Rev. 61: 33-48; 2009.
28. Johri, A.; Chaturvedi, R. K.; Beal, M. F. Hugging tight in Huntington's. Nat. Med 17 : 245-246; 2011.
29. Shirendeb, U. P.; Calkins, M. J.; Manczak, M.; Anekonda, V.; Dufour, B.; McBride, J. L.; Mao, P.; Reddy, P. H. Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease. Hum. Mol. Genet 21: 406-420; 2012.
30. Shacka, J. J.; Roth, K. A.; Zhang, J. The autophagy-lysosomal degradation pathway: role in neurodegenerative disease and therapy. Front. Biosci. 13: 718-736; 2008. (Pubitemid 351599777)
31. Twig, G.; Elorza, A.; Molina, A. J.; Mohamed, H.; Wikstrom, J. D.; Walzer, G.; Stiles, L.; Haigh, S. E.; Katz, S.; Las, G.; Alroy, J.; Wu, M.; Py, B. F.; Yuan, J.; Deeney, J. T.; Corkey, B. E.; Shirihai, O. S. Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. EMBO J. 27: 433-446; 2008. (Pubitemid 351161653)
32. Twig, G.; Shirihai, O. S. The interplay between mitochondrial dynamics and mitophagy. Antioxid. Redox Signal. 14: 1939-1951; 2011.
33. Rambold, A. S.; Kostelecky, B.; Elia, N.; Lippincott-Schwartz, J. Tubular network formation protects mitochondria from autophagosomal degradation during nutrient starvation. Proc. Natl. Acad. Sci. USA 108: 10190-10195; 2011.
34. Sawa, A.; Wiegand, G. W.; Cooper, J.; Margolis, R. L.; Sharp, A. H.; Lawler Jr J. F.; Greenamyre, J. T.; Snyder, S. H.; Ross, C. A. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat. Med 5: 119 4 -1198; 1999. (Pubitemid 29474426)
35. Martinez-Vicente, M.; Talloczy, Z.; Wong, E.; Tang, G.; Koga, H.; Kaushik, S.; de Vries, R.; Arias, E.; Harris, S.; Sulzer, D.; Cuervo, A. M. Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease. Nat. Neurosci. 13: 567-576; 2010.
36. Jahani-Asl, A.; Cheung, E. C.; Neuspiel, M.; MacLaurin, J. G.; Fortin, A.; Park, D. S.; McBride, H. M.; Slack, R. S. Mitofusin 2 protects cerebellar granule neurons against injury-induced cell death. J. Biol. Chem. 282: 23788-23798; 2007. (Pubitemid 47328040)
37. Barsoum, M. J.; Yuan, H.; Gerencser, A. A.; Liot, G.; Kushnareva, Y.; Graber, S.; Kovacs, I.; Lee, W. D.; Waggoner, J.; Cui, J.; White, A. D.; Bossy, B.; Martinou, J. C.; Youle, R. J.; Lipton, S. A.; Ellisman, M. H.; Perkins, G. A.; Bossy-Wetzel, E. Nitric oxide-induced mitochondrial fission is regulated by dynamin-related GTPases in neurons. EMBO J. 25: 3900-3911; 2006. (Pubitemid 44300275)
38. Valencia, A.; Sapp, E.; Kimm, J. S.; McClory, H.; Reeves, P. B.; Alexander, J.; Ansong, K. A.; Masso, N.; Frosch, M. P.; Kegel, K. B.; Li, X.; DiFiglia, M. Elevated NADPH oxidase activity contributes to oxidative stress and cell death in Huntington's disease. Hum. Mol. Genet 22: 111 2 -113 1 ; 2 0 1 3 .
39. Kovtun, I. V.; Liu, Y.; Bjoras, M.; Klungland, A.; Wilson, S. H.; McMurray, C. T. OGG1 initiates age-dependent CAG trinucleotide expansion in somatic cells. Nature 447: 447-452; 2007. (Pubitemid 46816735)
40. Browne, S. E.; Beal, M. F. Oxidative damage in Huntington's disease pathogenesis. Antioxid. Redox Signal. 8: 2061-2073; 2006. (Pubitemid 46489631)
41. Browne, S. E.; Ferrante, R. J.; Beal, M. F. Oxidative stress in Huntington's disease. Brain Pathol. 9: 147-163; 1999. (Pubitemid 29056525)
42. Stack, E. C.; Matson, W. R.; Ferrante, R. J. Evidence of oxidant damage in Huntington's disease: translational strategies using antioxidants. Ann. N. Y. Acad. Sci. 114 7 : 79-92; 2008.
43. Klepac, N.; Relja, M.; Klepac, R.; Hecimovic, S.; Babic, T.; Trkulja, V. Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects: a cross-sectional study. J. Neurol. 254: 1676-1683; 2007.
44. Sorolla, M. A.; Reverter-Branchat, G.; Tamarit, J.; Ferrer, I.; Ros, J.; Cabiscol, E. Proteomic and oxidative stress analysis in human brain samples of Hun-tington disease. Free Radic. Biol. Med. 45: 667-678; 2008.
45. Tasset, I.; Sanchez, F.; Tunez, I. [The molecular bases of Huntington's disease: the role played by oxidative stress]. Rev. Neurol. 49: 424-429; 2009.
46. Stoy, N.; Mackay, G. M.; Forrest, C. M.; Christofides, J.; Egerton, M.; Stone, T. W.; Darlington, L. G. Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J. Neurochem. 93: 611-623; 2005. (Pubitemid 40617621)
47. Chen, C. M.; Wu, Y. R.; Cheng, M. L.; Liu, J. L.; Lee, Y. M.; Lee, P. W.; Soong, B. W.; Chiu, D. T. Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients. Biochem. Biophys. Res. Commun. 359: 335-340; 2007. (Pubitemid 46880509)
48. Hersch, S. M.; Gevorkian, S.; Marder, K.; Moskowitz, C.; Feigin, A.; Cox, M.; Como, P.; Zimmerman, C.; Lin, M.; Zhang, L.; Ulug, A. M.; Beal, M. F.; Matson, W.; Bogdanov, M.; Ebbel, E.; Zaleta, A.; Kaneko, Y.; Jenkins, B.; Hevelone, N.; Zhang, H.; Yu, H.; Schoenfeld, D.; Ferrante, R.; Rosas, H. D. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 66: 250-252; 2006. (Pubitemid 43970166)
49. Tunez, I.; Sanchez-Lopez, F.; Aguera, E.; Fernandez-Bolanos, R.; Sanchez, F. M.; Tasset-Cuevas, I. Important role of oxidative stress biomarkers in Huntington's disease. J. Med. Chem. 54: 5602-5606; 2011.
50. Braak, H.; Braak, E. Allocortical involvement in Huntington's disease. Neuro-pathol. Appl. Neurobiol. 18: 539-547; 1992. (Pubitemid 23010156)
51. Tellez-Nagel, I.; Johnson, A. B.; Terry, R. D. Studies on brain biopsies of patients with Huntington's chorea. J. Neuropathol. Exp. Neurol. 33: 308-332; 1974.
52. Butterworth, N. J.; Williams, L.; Bullock, J. Y.; Love, D. R.; Faull, R. L.; Dragunow, M. Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum. Neuroscience 87: 49-53; 1998. (Pubitemid 28351167)
53. Portera-Cailliau, C.; Hedreen, J. C.; Price, D. L.; Koliatsos, V. E. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J. Neurosci. 15: 3775-3787; 1995.
54. Sorolla, M. A.; Rodriguez-Colman, M. J.; Tamarit, J.; Ortega, Z.; Lucas, J. J.; Ferrer, I.; Ros, J.; Cabiscol, E. Protein oxidation in Huntington disease affects energy production and vitamin B6 metabolism. Free Radic. Biol. Med. 49: 612-621; 2010.
55. Lim, D.; Fedrizzi, L.; Tartari, M.; Zuccato, C.; Cattaneo, E.; Brini, M.; Carafoli, E. Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease. J. Biol. Chem. 283: 5780-5789; 2008.
56. Tabrizi, S. J.; Cleeter, M. W.; Xuereb, J.; Taanman, J. W.; Cooper, J. M.; Schapira, A. H. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann. Neurol. 45: 25-32; 1999. (Pubitemid 29036428)
57. Patel, M.; Day, B. J.; Crapo, J. D.; Fridovich, I.; McNamara, J. O. Requirement for superoxide in excitotoxic cell death. Neuron 16: 345-355; 1996. (Pubitemid 26072367)
58. Perluigi, M.; Poon, H. F.; Maragos, W.; Pierce, W. M.; Klein, J. B. Calabrese, V.; Cini, C.; De Marco, C.; Butterfield, D. A. Proteomic analysis of protein expression and oxidative modification in r6/2 transgenic mice: a model of Huntington disease. Mol. Cell. Proteomics 4: 18 4 9 -1861; 20 05. (Pubitemid 41830180)
59. Acevedo-Torres, K.; Berrios, L.; Rosario, N.; Dufault, V.; Skatchkov, S.; Eaton, M. J.; Torres-Ramos, C. A.; Ayala-Torres, S.; Mitochondrial, DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Hunting-ton's disease. DNA Repair (Amst.) 8: 126-136; 2009.
60. Stack, C.; Ho, D.; Wille, E.; Calingasan, N. Y.; Williams, C.; Liby, K.; Sporn, M.; Dumont, M.; Beal, M. F. Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radic. Biol. Med. 49: 147-158; 2010.
61. Bogdanov, M. B.; Andreassen, O. A.; Dedeoglu, A.; Ferrante, R. J.; Beal, M. F. Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. J. Neurochem. 79: 1246-1249; 2001. (Pubitemid 34019802)
62. Siddiqui, A.; Rivera-Sanchez, S.; Castro Mdel, R.; Acevedo-Torres, K.; Rane, A.; Torres-Ramos, C. A.; Nicholls, D. G.; Andersen, J. K.; Ayala-Torres, S.; Mitochondrial, DNA damage is associated with reduced mitochondrial bioenergetics in Huntington's disease. Free Radic. Biol. Med. 53: 1478-1488; 2012.
63. Wang, J. Q.; Chen, Q.; Wang, X.; Wang, Q. C.; Wang, Y.; Cheng, H. P.; Guo, C.; Sun, Q.; Tang, T. S. Dysregulation of mitochondrial calcium signaling and superoxide flashes cause mitochondrial genomic DNA damage in Huntington disease. J. Biol. Chem. 288: 3070-3084; 2013.
64. Puigserver, P.; Wu, Z.; Park, C. W.; Graves, R.; Wright, M.; Spiegelman, B. M. A cold-inducible coactivator of nuclear receptors linked to adaptive thermo-genesis. Cell 92: 829-839; 1998. (Pubitemid 28155321)
65. Puigserver, P.; Spiegelman, B. M. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr. Rev 24: 78-90; 2003. (Pubitemid 36223280)
66. Liang, H.; Ward, W. F. PGC-1alpha: a key regulator of energy metabolism. Adv. Physiol. Educ. 30: 145-151; 20 06. (Pubitemid 44749372)
67. St-Pierre, J.; Drori, S.; Uldry, M.; Silvaggi, J. M.; Rhee, J.; Jager, S.; Handschin, C.; Zheng, K.; Lin, J.; Yang, W.; Simon, D. K.; Bachoo, R.; Spiegelman, B. M. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127: 397-408; 2006. (Pubitemid 44572377)
68. Lin, J.; Handschin, C.; Spiegelman, B. M. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 1: 361-370; 2005. (Pubitemid 43960626)
69. Kelly, D. P.; Scarpulla, R. C. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev. 18 : 357-368; 2004. (Pubitemid 38316342)
70. Handschin, C.; Spiegelman, B. M. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr. Rev. 27: 728-735; 2006. (Pubitemid 44936056)
71. St-Pierre, J.; Lin, J.; Krauss, S.; Tarr, P. T.; Yang, R.; Newgard, C. B.; Spiegelman, B. M. Bioenergetic analysis of peroxisome proliferator-activated receptor gamma coactivators 1alpha and 1beta (PGC-1alpha and PGC-1beta) in muscle cells. J. Biol. Chem. 278: 26597-26603; 2003. (Pubitemid 36876804)
72. Wu, Z.; Puigserver, P.; Andersson, U.; Zhang, C.; Adelmant, G.; Mootha, V.; Troy, A.; Cinti, S.; Lowell, B.; Scarpulla, R. C.; Spiegelman, B. M. Mechanisms controlling mitochondrial biogenesis and respiration through the thermo-genic coactivator PGC-1. Cell 98: 115 -124; 1999. (Pubitemid 29331201)
73. Cui, L.; Jeong, H.; Borovecki, F.; Parkhurst, C. N.; Tanese, N.; Krainc, D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127: 59-69; 2006. (Pubitemid 44466642)
74. Weydt, P.; Pineda, V. V.; Torrence, A. E.; Libby, R. T.; Satterfield, T. F.; Lazarowski, E. R.; Gilbert, M. L.; Morton, G. J.; Bammler, T. K.; Strand, A. D.; Cui, L.; Beyer, R. P.; Easley, C. N.; Smith, A. C.; Krainc, D.; Luquet, S.; Sweet, I. R.; Schwartz, M. W.; La Spada, A. R. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Hunting-ton's disease neurodegeneration. Cell Metab. 4: 349-362; 2006. (Pubitemid 44645069)
75. Chaturvedi, R. K.; Calingasan, N. Y.; Yang, L.; Hennessey, T.; Johri, A.; Beal, M. F. Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation. Hum. Mol. Genet 19: 3190-3205; 2010.
76. Johri, A.; Starkov, A. A.; Chandra, A.; Hennessey, T.; Sharma, A.; Orobello, S.; Squitieri, F.; Yang, L.; Beal, M. F. Truncated peroxisome proliferator-activated receptor-gamma coactivator 1alpha splice variant is severely altered in Huntington's disease. Neurodegener. Dis. 8: 496-503; 2011.
77. Lin, J.; Wu, P. H.; Tarr, P. T.; Lindenberg, K. S.; St-Pierre, J.; Zhang, C. Y.; Mootha, V. K.; Jager, S.; Vianna, C. R.; Reznick, R. M.; Cui, L.; Manieri, M.; Donovan, M. X.; Wu, Z.; Cooper, M. P.; Fan, M. C.; Rohas, L. M.; Zavacki, A. M.; Cinti, S.; Shulman, G. I.; Lowell, B. B.; Krainc, D.; Spiegelman, B. M. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 119 : 121-135; 2004. (Pubitemid 39349325)
78. Leone, T. C.; Lehman, J. J.; Finck, B. N.; Schaeffer, P. J.; Wende, A. R.; Boudina, S.; Courtois, M.; Wozniak, D. F.; Sambandam, N.; Bernal-Mizrachi, C.; Chen, Z.; Holloszy, J. O.; Medeiros, D. M.; Schmidt, R. E.; Saffitz, J. E.; Abel, E. D.; Semenkovich, C. F.; Kelly, D. P. PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol. 3:e101; 2005.
79. Chaturvedi, R. K.; Hennessey, T.; Johri, A.; Tiwari, S. K.; Mishra, D.; Agarwal, S.; Kim, Y. S.; Beal, M. F. Transducer of regulated CREB-binding proteins (TORCs) transcription and function is impaired in Huntington's disease. Hum. Mol. Genet 21: 3474-3488; 2012.
80. McConoughey, S. J.; Basso, M.; Niatsetskaya, Z. V.; Sleiman, S. F.; Smirnova, N. A.; Langley, B. C.; Mahishi, L.; Cooper, A. J.; Antonyak, M. A.; Cerione, R. A.; Li, B.; Starkov, A.; Chaturvedi, R. K.; Beal, M. F.; Coppola, G.; Geschwind, D. H.; Ryu, H.; Xia, L.; Iismaa, S. E.; Pallos, J.; Pasternack, R.; Hils, M.; Fan, J.; Raymond, L. A.; Marsh, J. L.; Thompson, L. M.; Ratan, R. R. Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. EMBO Mol. Med 2: 349-370; 2010.
81. Weydt, P.; Soyal, S. M.; Gellera, C.; Didonato, S.; Weidinger, C.; Oberkofler, H.; Landwehrmeyer, G. B.; Patsch, W. The gene coding for PGC-1alpha modifies age at onset in Huntington's Disease. Mol. Neurodegener 4: 3; 2009.
82. Taherzadeh-Fard, E.; Saft, C.; Andrich, J.; Wieczorek, S.; Arning, L. PGC-1alpha as modifier of onset age in Huntington disease. Mol. Neurodegener 4: 10; 2009.
83. Xiang, Z.; Valenza, M.; Cui, L.; Leoni, V.; Jeong, H. K.; Brilli, E.; Zhang, J.; Peng, Q.; Duan, W.; Reeves, S. A.; Cattaneo, E.; Krainc, D. Peroxisome-proliferator-activated receptor gamma coactivator 1 {alpha} contributes to dysmyelina-tion in experimental models of Huntington's disease. J. Neurosci. 31: 9544-9553; 2011.
84. Gomez-Tortosa, E.; MacDonald, M. E.; Friend, J. C.; Taylor, S. A.; Weiler, L. J.; Cupples, L. A.; Srinidhi, J.; Gusella, J. F.; Bird, E. D.; Vonsattel, J. P.; Myers, R. H. Quantitative neuropathological changes in presymptomatic Huntington's disease. Ann. Neurol. 49: 29-34; 2001. (Pubitemid 32163003)
85. Fennema-Notestine, C.; Archibald, S. L.; Jacobson, M. W.; Corey-Bloom, J.; Paulsen, J. S.; Peavy, G. M.; Gamst, A. C.; Hamilton, J. M.; Salmon, D. P.; Jernigan, T. L. In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease. Neurology 63: 989-995; 2004. (Pubitemid 39287905)
86. Reading, S. A.; Yassa, M. A.; Bakker, A.; Dziorny, A. C.; Gourley, L. M.; Yallapragada, V.; Rosenblatt, A.; Margolis, R. L.; Aylward, E. H.; Brandt, J.; Mori, S.; van Zijl, P.; Bassett, S. S.; Ross, C. A. Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study. Psychiatry Res. 140: 55-62; 2005. (Pubitemid 41443496)
87. Paulsen, J. S.; Langbehn, D. R.; Stout, J. C.; Aylward, E.; Ross, C. A.; Nance, M.; Guttman, M.; Johnson, S.; MacDonald, M.; Beglinger, L. J.; Duff, K.; Kayson, E.; Biglan, K.; Shoulson, I.; Oakes, D.; Hayden, M. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J. Neurol. Neurosurg. Psychiatry 79: 874-880; 2008.
88. Tabrizi, S. J.; Langbehn, D. R.; Leavitt, B. R.; Roos, R. A.; Durr, A.; Craufurd, D.; Kennard, C.; Hicks, S. L.; Fox, N. C.; Scahill, R. I.; Borowsky, B.; Tobin, A. J.; Rosas, H. D.; Johnson, H.; Reilmann, R.; Landwehrmeyer, B.; Stout, J. C. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 8: 791-801; 2009.
89. Rosas, H. D.; Lee, S. Y.; Bender, A. C.; Zaleta, A. K.; Vangel, M.; Yu, P.; Fischl, B.; Pappu, V.; Onorato, C.; Cha, J. H.; Salat, D. H.; Hersch, S. M. Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical disconnection. Neuroimage 49: 2995-3004; 2010.
90. Nopoulos, P. C.; Aylward, E. H.; Ross, C. A.; Mills, J. A.; Langbehn, D. R.; Johnson, H. J.; Magnotta, V. A.; Pierson, R. K.; Beglinger, L. J.; Nance, M. A.; Barker, R. A.; Paulsen, J. S. Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. Brain 134: 137-142; 2011.
91. Bartzokis, G.; Lu, P. H.; Tishler, T. A.; Fong, S. M.; Oluwadara, B.; Finn, J. P.; Huang, D.; Bordelon, Y.; Mintz, J.; Perlman, S. Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications. Neurochem. Res. 32: 1655-1664; 2007. (Pubitemid 47428858)
92. Lin, J.; Wu, H.; Tarr, P. T.; Zhang, C. Y.; Wu, Z.; Boss, O.; Michael, L. F.; Puigserver, P.; Isotani, E.; Olson, E. N.; Lowell, B. B.; Bassel-Duby, R.; Spiegelman, B. M. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 418: 797-801; 2002.
93. Handschin, C.; Chin, S.; Li, P.; Liu, F.; Maratos-Flier, E.; Lebrasseur, N. K.; Yan, Z.; Spiegelman, B. M. Skeletal muscle fiber-type switching, exercise intolerance, and myopathy in PGC-1alpha muscle-specific knock-out animals. J. Biol. Chem. 282: 30014-30021; 2007. (Pubitemid 350035265)
94. Gizatullina, Z. Z.; Lindenberg, K. S.; Harjes, P.; Chen, Y.; Kosinski, C. M.; Landwehrmeyer, B. G.; Ludolph, A. C.; Striggow, F.; Zierz, S.; Gellerich, F. N. Low stability of Huntington muscle mitochondria against Ca2+ in R6/2 mice. Ann. Neurol. 59: 407-411; 2006. (Pubitemid 43202500)
95. Kosinski, C. M.; Schlangen, C.; Gellerich, F. N.; Gizatullina, Z.; Deschauer, M.; Schiefer, J.; Young, A. B.; Landwehrmeyer, G. B.; Toyka, K. V.; Sellhaus, B.; Lindenberg, K. S. Myopathy as a first symptom of Huntington's disease in a Marathon runner. Mov. Disord 22: 1637-1640; 2007. (Pubitemid 47477928)
96. Turner, C.; Cooper, J. M.; Schapira, A. H. Clinical correlates of mitochondrial function in Huntington's disease muscle. Mov. Disord 22: 17 15 -17 21 ; 2 0 0 7 . (Pubitemid 47597594)
97. Johri, A.; Beal, M. F. Antioxidants in Huntington's disease. Biochim. Biophys. Acta 1822: 664-674; 2012.
98. Hinerfeld, D.; Traini, M. D.; Weinberger, R. P.; Cochran, B.; Doctrow, S. R.; Harry, J.; Melov, S. Endogenous mitochondrial oxidative stress: neurodegen-eration, proteomic analysis, specific respiratory chain defects, and efficacious antioxidant therapy in superoxide dismutase 2 null mice. J. Neurochem. 88: 657-667; 2004. (Pubitemid 38140210)
99. Chiang, M. C.; Chen, C. M.; Lee, M. R.; Chen, H. W.; Chen, H. M.; Wu, Y. S.; Hung, C. H.; Kang, J. J.; Chang, C. P.; Chang, C.; Wu, Y. R.; Tsai, Y. S.; Chern, Y. Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma. Hum. Mol. Genet 19: 4043-4058; 2010.
100. Quintanilla, R. A.; Jin, Y. N.; Fuenzalida, K.; Bronfman, M.; Johnson, G. V. Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease. J. Biol. Chem. 283: 25628-25637; 2008.
101. Viscomi, C.; Bottani, E.; Civiletto, G.; Cerutti, R.; Moggio, M.; Fagiolari, G.; Schon, E. A.; Lamperti, C.; Zeviani, M. In vivo correction of COX deficiency by activation of the AMPK/PGC-1alpha axis. Cell Metab. 14: 80-90; 2011.
102. Yatsuga, S.; Suomalainen, A. Effect of bezafibrate treatment on late-onset mitochondrial myopathy in mice. Hum. Mol. Genet 21: 526-535; 2012.
103. Demetri, G. D.; Fletcher, C. D.; Mueller, E.; Sarraf, P.; Naujoks, R.; Campbell, N.; Spiegelman, B. M.; Singer, S. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc. Natl. Acad. Sci. USA 96: 3951-3956; 1999. (Pubitemid 29169017)
104. Suh, N.; Wang, Y.; Williams, C. R.; Risingsong, R.; Gilmer, T.; Willson, T. M.; Sporn, M. B. A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Res. 59: 5671-5673; 1999.
105. Kersten, S.; Desvergne, B.; Wahli, W. Roles of PPARs in health and disease. Nature 405: 421-424; 2000. (Pubitemid 30367411)
106. Park, S. J.; Ahmad, F.; Philp, A.; Baar, K.; Williams, T.; Luo, H.; Ke, H.; Rehmann, H.; Taussig, R.; Brown, A. L.; Kim, M. K.; Beaven, M. A.; Burgin, A. B.; Manganiello, V.; Chung, J. H. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148: 421-433; 2012.
107. Kumar, P.; Padi, S. S.; Naidu, P. S.; Kumar, A. Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms. Behav. Pharmacol. 17: 485-492; 2006. (Pubitemid 44325810)
108. Binienda, Z. K.; Beaudoin, M. A.; Gough, B.; Ali, S. F.; Virmani, A. Assessment of 3-nitropropionic acid-evoked peripheral neuropathy in rats: neuroprotec-tive effects of acetyl-l-carnitine and resveratrol. Neurosci. Lett. 480: 117 -121; 2010.
109. Ho, D. J.; Calingasan, N. Y.; Wille, E.; Dumont, M.; Beal, M. F. Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease. Exp. Neurol. 225: 74-84; 2010.
110. Pearson, K. J.; Baur, J. A.; Lewis, K. N.; Peshkin, L.; Price, N. L.; Labinskyy, N.; Swindell, W. R.; Kamara, D.; Minor, R. K.; Perez, E.; Jamieson, H. A.; Zhang, Y.; Dunn, S. R.; Sharma, K.; Pleshko, N.; Woollett, L. A.; Csiszar, A.; Ikeno, Y.; Le Couteur, D.; Elliott, P. J.; Becker, K. G.; Navas, P.; Ingram, D. K.; Wolf, N. S.; Ungvari, Z.; Sinclair, D. A. de Cabo, R. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 8: 157-168; 2008.
111. Jiang, M.; Wang, J.; Fu, J.; Du, L.; Jeong, H.; West, T.; Xiang, L.; Peng, Q.; Hou, Z.; Cai, H.; Seredenina, T.; Arbez, N.; Zhu, S.; Sommers, K.; Qian, J.; Zhang, J.; Mori, S.; Yang, X. W.; Tamashiro, K. L.; Aja, S.; Moran, T. H.; Luthi-Carter, R.; Martin, B.; Maudsley, S.; Mattson, M. P.; Cichewicz, R. H.; Ross, C. A.; Holtzman, D. M.; Krainc, D.; Duan, W. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat. Med 18: 153-158; 2011.
112. Jeong, H.; Cohen, D. E.; Cui, L.; Supinski, A.; Savas, J. N.; Mazzulli, J. R.; Yates, J. R. 3rd; Bordone, L.; Guarente, L.; Krainc, D. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat. Med 18: 159-165; 2011.
113. Fu, J.; Jin, J.; Cichewicz, R. H.; Hageman, S. A.; Ellis, T. K.; Xiang, L.; Peng, Q.; Jiang, M.; Arbez, N.; Hotaling, K.; Ross, C. A.; Duan, W. trans-(-)-epsilon-Viniferin increases mitochondrial sirtuin 3 (SIRT3), activates AMP-activated protein kinase (AMPK), and protects cells in models of Huntington Disease. J. Biol. Chem. 287: 24460-24472; 2012.
114. Ozden, O.; Park, S. H.; Kim, H. S.; Jiang, H.; Coleman, M. C.; Spitz, D. R.; Gius, D. Acetylation of MnSOD directs enzymatic activity responding to cellular nutrient status or oxidative stress. Aging (Albany NY) 3: 102-107; 2011.
115. Qiu, X.; Brown, K.; Hirschey, M. D.; Verdin, E.; Chen, D. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab. 12: 662-667; 2010.
116. Tao, R.; Coleman, M. C.; Pennington, J. D.; Ozden, O.; Park, S. H.; Jiang, H.; Kim, H. S.; Flynn, C. R.; Hill, S.; Hayes McDonald, W.; Olivier, A. K.; Spitz, D. R.; Gius, D. Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol. Cell 40: 893-904; 2010.
117. Chen, Y.; Zhang, J.; Lin, Y.; Lei, Q.; Guan, K. L.; Zhao, S.; Xiong, Y. Tumour suppressor SIRT3 deacetylates and activates manganese superoxide dismu-tase to scavenge ROS. EMBO Rep. 12: 534-541; 2011.
118. Hirschey, M. D.; Shimazu, T.; Jing, E.; Grueter, C. A.; Collins, A. M.; Aouizerat, B.; Stancakova, A.; Goetzman, E.; Lam, M. M.; Schwer, B.; Stevens, R. D.; Muehlbauer, M. J.; Kakar, S.; Bass, N. M.; Kuusisto, J.; Laakso, M.; Alt, F. W.; Newgard, C. B.; Farese Jr R. V.; Kahn, C. R.; Verdin, E. SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol. Cell 44: 17 7 -190; 2011.
119. Tsunemi, T.; Ashe, T. D.; Morrison, B. E.; Soriano, K. R.; Au, J.; Roque, R. A.; Lazarowski, E. R.; Damian, V. A.; Masliah, E.; La Spada, A. R. PGC-1alpha rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci. Transl. Med. 4: 142ra197; 2012.
120. Settembre, C.; Di Malta, C.; Polito, V. A.; Garcia Arencibia, M.; Vetrini, F.; Erdin, S.; Erdin, S. U.; Huynh, T.; Medina, D.; Colella, P.; Sardiello, M.; Rubinsztein, D. C.; Ballabio, A. TFEB links autophagy to lysosomal biogenesis. Science 332: 1429-1433; 2011.
121. Chiang, M. C.; Chern, Y.; Huang, R. N. PPARgamma rescue of the mitochon-drial dysfunction in Huntington's disease. Neurobiol. Dis. 45: 322-328; 2012.
122. Jin, Y. N.; Hwang, W. Y.; Jo, C.; Johnson, G. V. Metabolic state determines sensitivity to cellular stress in Huntington disease: normalization by activation of PPARgamma. PLoS One 7:e30406; 2012.
123. Yang, T.; Chan, N. Y.; Sauve, A. A. Syntheses of nicotinamide riboside and derivatives: effective agents for increasing nicotinamide adenine dinucleo-tide concentrations in mammalian cells. J. Med. Chem. 50: 6458-6461; 2007. (Pubitemid 350309084)
124. Jiang, J.; Kurnikov, I.; Belikova, N. A.; Xiao, J.; Zhao, Q.; Amoscato, A. A.; Braslau, R.; Studer, A.; Fink, M. P.; Greenberger, J. S.; Wipf, P.; Kagan, V. E. Structural requirements for optimized delivery, inhibition of oxidative stress, and antiapoptotic activity of targeted nitroxides. J. Pharmacol. Exp. Ther. 320: 1050-1060; 2007. (Pubitemid 46294048)
125. Xun, Z.; Rivera-Sanchez, S.; Ayala-Pena, S.; Lim, J.; Budworth, H.; Skoda, E. M.; Robbins, P. D.; Niedernhofer, L. J.; Wipf, P.; McMurray, C. T. Targeting of XJB-5-131 to mitochondria suppresses oxidative DNA damage and motor decline in a mouse model of Huntington's disease. Cell Rep 2: 1137 -1142; 2012.
126. Ellrichmann, G.; Petrasch-Parwez, E.; Lee, D. H.; Reick, C.; Arning, L.; Saft, C.; Gold, R.; Linker, R. A. Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's diseae. PLoS One 6:e16172; 2011.